Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma

<b>Background/Objectives:</b> Multiple Myeloma (MM) is a hematologic malignancy caused by clonally expanded plasma cells that produce a monoclonal immunoglobulin (M-protein), a personalized biomarker. Recently, we developed an ultra-sensitive mass spectrometry method to quantify minimal...

Full description

Saved in:

Bibliographic Details
Main Authors:	Charissa Wijnands, Peter G. A. Karel, Jolein Gloerich, Gad Armony, Anastasia Tzasta, Corrie M. de Kat Angelino, Luciano Di Stefano, Vincent Bonifay, Theo M. Luider, Martijn M. VanDuijn, Sandra J. Croockewit, Elizabeth A. de Kort, Daan A. R. Castelijn, Claudia A. M. Stege, Hans J. C. T. Wessels, Alain J. van Gool, Niels W. C. J. van de Donk, Joannes F. M. Jacobs
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Series:	Pharmaceutics
Subjects:	multiple myeloma therapeutic drug monitoring minimal residual disease therapy response kinetics therapeutic antibody bispecific antibody
Online Access:	https://www.mdpi.com/1999-4923/17/1/135
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma

Similar Items